Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chong Kun Dang Holdings Corp. (001630.KS)
KRW39,300.00
-100.00 (-0.25%)
KR KSC Healthcare Drug Manufacturers - Specialty & Generic
Address
8, Chungjeong-ro
Seoul, KR
Seoul, KR
CEO
Hee-Nam Choi
IPO
2000-01-04
ISIN KR7001630003
Description
Based in Seoul, South Korea, Chong Kun Dang Holdings Corp. has manufactured and supplied pharmaceutical goods since its inception in 1941, reaching both South Korean and global markets.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
KRW39,300.00
-100.00 (-0.25%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
7.7K
Beta
0.51
Float Shares
2.36M
Free Float %
49.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.33% | -0.54% | -6.73% | -14.80% | -4.39% | +0.88% | -4.39% | -9.94% | -57.64% | -48.25% | +225.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
39,300.00
DCF (Unlevered)
340,600.46
+766.7%
DCF (Levered)
684,677.93
+1,642.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2025-06 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.19
Distress
Piotroski F-Score
5 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B+
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+0.1% Q1'26: -2.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+19.3% ★ Q1'26: +106.2% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+1.6% Q1'26: +2.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+6.1% Q1'26: +8.2% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+3.6% Q1'26: +5.1% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+5.2% Q1'26: +5.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×5.29× Q1'26: 4.60× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
221.83B
est: 636.50B (-65.1%)
|
335.68B
est: 164.00B (+104.7%)
|
450.74B
est: 15.00B (+2,904.9%)
|
531.11B
est: 20.10B (+2,542.4%)
|
720.64B
est: 690.40B (+4.4%)
|
858.12B
est: 474.00B (+81.0%)
|
925.98B
est: 967.00B (-4.2%)
|
908.96B
est: 1.04T (-12.9%)
|
879.78B
est: 878.00B (+0.2%)
|
957.75B
est: 924.00B (+3.7%)
|
959.01B
est: 1.03T (-7.3%)
|
1.11T
1.11T – 1.11T
+7.0% YoY
|
1.20T
1.20T – 1.20T
+8.7% YoY
|
| EBITDA |
36.13B
est: 53.47B (-32.4%)
|
39.72B
est: 13.78B (+188.3%)
|
67.57B
est: 1.26B (+5,262.3%)
|
77.83B
est: 1.69B (+4,509.2%)
|
128.57B
est: 58.00B (+121.7%)
|
132.19B
est: 39.82B (+232.0%)
|
72.54B
est: 81.23B (-10.7%)
|
13.61B
est: 87.70B (-84.5%)
|
56.07B
est: 73.76B (-24.0%)
|
104.32B
est: 163.07B (-36.0%)
|
102.31B
est: 182.64B (-44.0%)
|
195.46B
195.46B – 195.46B
+7.0% YoY
|
212.49B
212.49B – 212.49B
+8.7% YoY
|
| EBIT |
34.16B
est: 25.73B (+32.8%)
|
50.29B
est: 6.63B (+658.7%)
|
80.84B
est: 606.32M (+13,232.3%)
|
68.85B
est: 812.47M (+8,373.5%)
|
101.06B
est: 27.91B (+262.1%)
|
101.85B
est: 19.16B (+431.6%)
|
36.80B
est: 39.09B (-5.8%)
|
-32.88B
est: 42.20B (-177.9%)
|
10.79B
est: 35.49B (-69.6%)
|
60.98B
est: 115.56B (-47.2%)
|
58.28B
est: 129.43B (-55.0%)
|
138.51B
138.51B – 138.51B
+7.0% YoY
|
150.58B
150.58B – 150.58B
+8.7% YoY
|
| Net Income |
15.21B
est: 61.49B (-75.3%)
|
29.43B
est: 8.61B (+241.9%)
|
48.01B
est: 8.56B (+461.1%)
|
27.46B
est: 11.77B (+133.2%)
|
79.33B
est: 12.68B (+525.5%)
|
78.68B
est: 67.63B (+16.3%)
|
15.99B
est: 28.16B (-43.2%)
|
1.07B
est: 33.77B (-96.8%)
|
47.01B
est: 32.89B (+42.9%)
|
33.60B
est: 7.80B (+330.7%)
|
40.43B
est: 22.15B (+82.5%)
|
28.62B
28.62B – 28.62B
+29.2% YoY
|
32.86B
32.86B – 32.86B
+14.8% YoY
|
| SGA |
17.90B
est: 211.87B (-91.6%)
|
40.63B
est: 54.59B (-25.6%)
|
70.64B
est: 4.99B (+1,314.7%)
|
89.72B
est: 6.69B (+1,240.9%)
|
168.61B
est: 229.81B (-26.6%)
|
236.97B
est: 157.78B (+50.2%)
|
318.40B
est: 321.89B (-1.1%)
|
331.77B
est: 347.52B (-4.5%)
|
327.49B
est: 292.26B (+12.1%)
|
294.13B
est: 303.10B (-3.0%)
|
241.64B
est: 339.48B (-28.8%)
|
363.30B
363.30B – 363.30B
+7.0% YoY
|
394.95B
394.95B – 394.95B
+8.7% YoY
|
| EPS |
3,914.00
est: 12,915.00 (-69.7%)
|
6,630.00
est: 1,808.00 (+266.7%)
|
9,766.00
est: 1,797.00 (+443.5%)
|
5,481.00
est: 2,473.00 (+121.6%)
|
15,834.00
est: 2,664.00 (+494.4%)
|
15,711.00
est: 14,204.00 (+10.6%)
|
3,212.00
est: 5,915.00 (-45.7%)
|
219.00
est: 7,092.00 (-96.9%)
|
9,743.89
est: 6,909.00 (+41.0%)
|
7,059.01
est: 1,557.00 (+353.4%)
|
8,492.65
est: 4,422.00 (+92.1%)
|
5,712.00
5,712.00 – 5,712.00
+29.2% YoY
|
6,559.00
6,559.00 – 6,559.00
+14.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | B+ | 3/5 | 1/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | B+ | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B | 3/5 | 1/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
34.01B
OE per share TTM
9,737.91
Owner's Yield
15.56%
Maintenance CapEx ratio
190.72%
Maint CapEx / Avg PPE
52.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 7 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex KOSPI 226490.KS | 0.01% | 43.0K | 0.15% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 80.1K | 0.39% |
| 3 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 13.6K | 0.46% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 43.4K | 0.28% |
| 5 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 206.72 | 0.56% |
| 6 | Dimensional Emerging Markets Sustainability Core 1 ETF DFSE | 0.00% | 310.46 | 0.44% |
| 7 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 2.9K | 0.33% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
1.58B
Shares Outstanding
4.76M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hee-Nam Choi | Chief Executive Officer, President & Chairman | — | male |
| KiSeong Lee | Financial Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 001630.KS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
